Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

719 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.
Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec JY, Robert C, Carbonnel F, Chaput N. Coutzac C, et al. Among authors: scoazec jy. J Crohns Colitis. 2017 Oct 1;11(10):1238-1246. doi: 10.1093/ecco-jcc/jjx081. J Crohns Colitis. 2017. PMID: 28967957
Arterial thrombosis and anti-PD-1 blockade.
Boutros C, Scoazec JY, Mateus C, Routier E, Roy S, Robert C. Boutros C, et al. Among authors: scoazec jy. Eur J Cancer. 2018 Mar;91:164-166. doi: 10.1016/j.ejca.2017.11.018. Epub 2017 Dec 27. Eur J Cancer. 2018. PMID: 29289455 No abstract available.
CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17.
Corgnac S, Malenica I, Mezquita L, Auclin E, Voilin E, Kacher J, Halse H, Grynszpan L, Signolle N, Dayris T, Leclerc M, Droin N, de Montpréville V, Mercier O, Validire P, Scoazec JY, Massard C, Chouaib S, Planchard D, Adam J, Besse B, Mami-Chouaib F. Corgnac S, et al. Among authors: scoazec jy. Cell Rep Med. 2020 Oct 20;1(7):100127. doi: 10.1016/j.xcrm.2020.100127. eCollection 2020 Oct 20. Cell Rep Med. 2020. PMID: 33205076 Free PMC article.
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy.
Asrir A, Tardiveau C, Coudert J, Laffont R, Blanchard L, Bellard E, Veerman K, Bettini S, Lafouresse F, Vina E, Tarroux D, Roy S, Girault I, Molinaro I, Martins F, Scoazec JY, Ortega N, Robert C, Girard JP. Asrir A, et al. Among authors: scoazec jy. Cancer Cell. 2022 Mar 14;40(3):318-334.e9. doi: 10.1016/j.ccell.2022.01.002. Epub 2022 Feb 3. Cancer Cell. 2022. PMID: 35120598 Free article.
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Nebot-Bral L, Hollebecque A, Yurchenko AA, de Forceville L, Danjou M, Jouniaux JM, Rosa RCA, Pouvelle C, Aoufouchi S, Vuagnat P, Smolenschi C, Colomba E, Leary A, Marabelle A, Scoazec JY, Cassard L, Nikolaev S, Chaput N, Kannouche P. Nebot-Bral L, et al. Among authors: scoazec jy. J Immunother Cancer. 2022 Jul;10(7):e005059. doi: 10.1136/jitc-2022-005059. J Immunother Cancer. 2022. PMID: 35896284 Free PMC article.
Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
Moya-Plana A, Herrera Gómez RG, Rossoni C, Dercle L, Ammari S, Girault I, Roy S, Scoazec JY, Vagner S, Janot F, Eggermont AMM, Robert C. Moya-Plana A, et al. Among authors: scoazec jy. Cancer Immunol Immunother. 2019 Jul;68(7):1171-1178. doi: 10.1007/s00262-019-02351-7. Epub 2019 Jun 7. Cancer Immunol Immunother. 2019. PMID: 31172258 Free PMC article.
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.
Facchinetti F, Lacroix L, Mezquita L, Scoazec JY, Loriot Y, Tselikas L, Gazzah A, Rouleau E, Adam J, Michiels S, Massard C, André F, Olaussen KA, Vassal G, Howarth K, Besse B, Soria JC, Friboulet L, Planchard D. Facchinetti F, et al. Among authors: scoazec jy. Eur J Cancer. 2020 Jun;132:211-223. doi: 10.1016/j.ejca.2020.03.025. Epub 2020 May 6. Eur J Cancer. 2020. PMID: 32388065
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.
Pasqualini C, Rubino J, Brard C, Cassard L, André N, Rondof W, Scoazec JY, Marchais A, Nebchi S, Boselli L, Grivel J, Aerts I, Thebaud E, Paoletti X, Minard-Colin V, Vassal G, Geoerger B. Pasqualini C, et al. Among authors: scoazec jy. Eur J Cancer. 2021 Jun;150:53-62. doi: 10.1016/j.ejca.2021.03.032. Epub 2021 Apr 20. Eur J Cancer. 2021. PMID: 33892407 Clinical Trial.
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L. Facchinetti F, et al. Among authors: scoazec jy. Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. doi: 10.1158/1078-0432.CCR-16-0917. Epub 2016 Jul 11. Clin Cancer Res. 2016. PMID: 27401242 Clinical Trial.
719 results